NCT07399132

A Study of APL-10456-Vaccine

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Immunogenicity of APL-10456-Vaccine in Healthy Volunteers

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 144 (estimated)
• Sponsor: Apollo Therapeutics Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers

Conditions

• Rhinovirus

Interventions

Type	Name	Description
DRUG	APL-10456-Vaccine	3 cohorts are planned for Part A and Part B
OTHER	Placebo	Placebo (a saline) is comparator to study vaccine

Timeline

• Start date: 2026-02-16
• Primary completion: 2026-08-02
• Completion: 2027-10-21
• First posted: 2026-02-10
• Last updated: 2026-02-19

Locations

1 site across 1 country: Australia